MILESTONES
DEVA "Doktor, Eczacı ve Alatları" (Physicians, Pharmacists and Diagnostics) Sanayi ve Ticaret A.Ş. was incorporated.
The first manufacturing facility is established in Tünel, Beyoğlu.
Bomonti pharmaceutical plant was opened.
The ampoule plant was set up.
The production of Tetracycline and Oxytetracycline was realized as the first pharmaceutical raw material in Turkey. The title and status of the Company was changed from DEVA "Doktorlar Ecza ve Alat" (Physicians Drugs and Equipment) Sanayi ve Ticaret Anonim Şirketi to DEVA Holding A.Ş.
The largest pharmaceutical manufacturing facility was purchased from Farmitalia.
Carlo Erba pharmaceutical plant was purchased.
With the production of Gentamicine in its active pharmaceutical ingredient manufacturing facilities, it was listed among 5 establishments to produce this active ingredient throughout the world.
A detergent and cologne factory was set up in İzmit.
The capital of DEVA Holding A.Ş. was increased to TL 1 billion and the number of shareholders reached 6,000.
The shares of DEVA Holding started to be traded on the Istanbul Stock Exchange.
The production of lincomycin (antibiotic) was started at the "pharmaceutical active ingredient" manufacturing facilities.
The foundation of the synthesis plant were laid in Çerkezköy.
ANSA A.Ş. was purchased by DEVA Holding, the title of the firm was changed as DEPA A.Ş. With the production of Potassium Clavulanate, the company accomplished being one of only five establishments in the world capable of producing this active ingredient.
The capital of DEVA Holding A.Ş. was increased to TL 4 trillion and the number of shareholders reached 15,000.
DEVA Holding ranked among the top 10 pharmaceutical companies of Turkey with USD 120 million sales on box basis and a market share of 4,6%. The equity capital of the company was increased to TRY 48 million. Amoklavin became the best selling drug of the year in Turkey.
The majority ownership of DEVA Holding was transferred to EastPharma Limited, a business venture of GEM Global Equities Management S.A. In connection with this restructuring, Phillip Haas was elected as the new Chairman of the Board of Directors in July 2006.
The company headquarters moved to its new building in Halkalı. Production plant construction was started in çerkezköy and Köseköy İzmit. Representative offices were opened in Georgia, Russia (Moscow), Azerbaijan and Uzbekistan.
50 years of success in the sector was celebrated together with doctors and pharmacists all around Turkey.
Inhaler manufacturing site opened. FDA ANDA submission 107 approval in 19 countries inc. Germany, Switzerland, Holland, Australia, New Zeland.
DEVA was honored with the Gold Mortar Award in the Research and Development category at the 12th Golden Mortar Awards, one of the pharmaceutical industry's most prestigious accolades, organized by Eczacı Dergisi.
According to the Ar-Ge 250 Research prepared by Turkishtime, DEVA was selected as Turkey's leading pharmaceutical company in allocating resources to Research and Development.
DEVA Holding celebrated its successful 65th year in the industry.
The license approvals reached 1,119 in 65 countries.
As part of disaster management, the DEVA Search and Rescue Team (DEVARK), composed of volunteer employees capable of undertaking responsibilities both within the company and at the national level, has been established.
We are moving towards the future with our new 'Values'!
